Silver Nanoparticles Irrigant

PreclinicalSmall molecule

Silver Nanoparticles Irrigant is one of 77 small molecule programs targeting Diabetic Foot. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic FootActive, not recruiting

Post Operative PainCompleted

Diabetic FootPreclinical

Active, not recruiting

Post Operative PainPreclinical

Completed

Competition

Competitive Landscape

61 competitors in Post Operative Pain

#DrugCompanyPhaseTrials

Marcaine

IInnocoll

Approved

25 2

Advil

KKenvue Brands

Approved

16 3

Duragesic

CCephalon

Approved

11 4

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

10 5

Oxycontin

PProtega

Approved

9 6

Ketalar

AAultman Health Foundation

Approved

9 7

Epsom Salt

FFresenius Kabi USA, LLC

Approved

7 8

Tylenol

KKenvue Brands

Approved

6 9

Achromycin V

WWyeth-Lederle Vaccines

Approved

1 10

EXPAREL

Pacira Pharmaceuticals, Inc

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diabetic Foot1 trial

Comparative Study of Negative-Pressure Wound Therapy Integrated With Silver Nanoparticle Spray Versus Negative-Pressure Wound Therapy in Post-Revascularization Diabetic Foot Wound Management

Enrolling by invitation·KKafrelsheikh University··NCT07147790·100 enrolled

Post Operative Pain1 trial

Evaluation of Antimicrobial Efficacy and Postoperative Pain After Using Silver Nanoparticles and Chitosan Nanoparticles Against Enterococcus Faecalis and Candida Albicans Biofilm

Completed·MMinia University·N/A·NCT06172023·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Silver Nanoparticles Irrigant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Silver Nanoparticles Irrigant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Silver Nanoparticles Irrigant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Minia University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMinia University

Silver Nanoparticles Irrigant

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diabetic Foot1 trial

Post Operative Pain1 trial

References

Drug Info

Quick Facts

Related News